LifeMD (LFMD) Projected to Post Earnings on Monday

LifeMD (NASDAQ:LFMD) is projected to post its Q4 2025 results after the market closes on Monday, March 9th. Analysts expect LifeMD to post earnings of ($0.01) per share and revenue of $48.5720 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 9, 2026 at 4:30 PM ET.

LifeMD Stock Performance

LFMD stock opened at $2.67 on Monday. The company has a market capitalization of $128.53 million, a P/E ratio of -15.71 and a beta of 1.92. The company has a fifty day moving average price of $3.36 and a 200-day moving average price of $4.72. LifeMD has a 52-week low of $2.56 and a 52-week high of $15.84.

Insider Activity at LifeMD

In other news, CMO Jessica Friedeman sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $3.61, for a total value of $54,150.00. Following the transaction, the chief marketing officer owned 205,000 shares in the company, valued at $740,050. This trade represents a 6.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 18.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd bought a new stake in LifeMD during the 4th quarter valued at $36,000. Jain Global LLC purchased a new position in shares of LifeMD in the fourth quarter valued at $45,000. Quarry LP bought a new stake in shares of LifeMD during the 3rd quarter valued at $52,000. Tower Research Capital LLC TRC lifted its holdings in LifeMD by 110.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after purchasing an additional 2,452 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in LifeMD by 18.8% in the 4th quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock worth $83,000 after purchasing an additional 3,870 shares during the period. 35.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on LFMD. BTIG Research cut their target price on LifeMD from $18.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Wall Street Zen lowered LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. Mizuho reduced their target price on LifeMD from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, November 19th. Weiss Ratings restated a “sell (e+)” rating on shares of LifeMD in a report on Monday, December 29th. Finally, Loop Capital set a $8.00 price objective on shares of LifeMD in a research note on Monday, November 24th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.25.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.